Associations between serum clusterin levels and non-alcoholic fatty liver disease

Objective Clusterin is closely correlated with insulin resistance and its associated comorbidities. This study aimed to investigate the correlation between serum clusterin levels and non-alcoholic fatty liver disease (NAFLD) and further explore the mediating role of insulin resistance in this relationship. Methods This study enrolled 195 inpatients (41 males and 154 females) aged 18–61 years. Twenty-four patients were followed up for 12 months after bariatric surgery. Serum clusterin levels were measured using a sandwich enzyme-linked immunosorbent assay. Fatty liver disease was diagnosed on the basis of liver ultrasonography. The fatty liver index (FLI) was calculated to quantify the degree of hepatic steatosis. The mediating role of homeostasis model assessment-insulin resistance (HOMA-IR) was assessed using mediation analysis. Results Participants with NAFLD had significantly higher serum clusterin levels than those without NAFLD (444.61 (325.76–611.52) mg/L vs 294.10 (255.20–373.55) mg/L, P < 0.01). With increasing tertiles of serum clusterin levels, the prevalence of NAFLD displayed an upward trend (P < 0.01). Multivariate linear regression analysis showed that serum clusterin levels were a positive determinant of FLI (standardized β = 0.271, P < 0.001) after adjusting for multiple metabolic risk factors. Serum clusterin levels significantly decreased after bariatric surgery (298.77 (262.56–358.10) mg/L vs 520.55 (354.94–750.21) mg/L, P < 0.01). In the mediation analysis, HOMA-IR played a mediating role in the correlation between serum clusterin levels and FLI; the estimated percentage of the total effect was 17.3%. Conclusion Serum clusterin levels were associated with NAFLD. In addition, insulin resistance partially mediated the relationship between serum clusterin levels and FLI.

[1]  Yufei Wang,et al.  FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation , 2022, Obesity.

[2]  Joshua E. Elias,et al.  Exercise plasma boosts memory and dampens brain inflammation via clusterin , 2021, Nature.

[3]  Shinwu Jeong,et al.  Clusterin, other extracellular chaperones, and eye disease , 2021, Progress in Retinal and Eye Research.

[4]  Chun‐Hsiang Wang,et al.  Sterol O-acyltransferase 2 chaperoned by apolipoprotein J facilitates hepatic lipid accumulation following viral and nutrient stresses , 2021, Communications Biology.

[5]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[6]  David Bradley,et al.  Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome , 2021, Frontiers in Immunology.

[7]  S. Patra,et al.  Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[8]  Hyeon Soo Kim,et al.  Clusterin overexpression protects against western diet-induced obesity and NAFLD , 2020, Scientific Reports.

[9]  C. González-Martín,et al.  Clusterin: Always protecting. Synthesis, function and potential issues. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Eosu Kim,et al.  Plasma clusterin as a potential link between diabetes and Alzheimer's disease. , 2020, The Journal of clinical endocrinology and metabolism.

[11]  K. Park,et al.  Author Correction: Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity , 2020, Nature Communications.

[12]  H. Tilg,et al.  NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.

[13]  Bo Hyun Kim,et al.  Combined Aerobic and Resistance Exercise Training Reduces Circulating Apolipoprotein J Levels and Improves Insulin Resistance in Postmenopausal Diabetic Women , 2020, Diabetes & metabolism journal.

[14]  H. Pan,et al.  High serum clusterin levels are associated with premature coronary artery disease in a Chinese population , 2019, Diabetes/metabolism research and reviews.

[15]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[16]  Stephen T. C. Wong,et al.  Clusterin Impairs Hepatic Insulin Sensitivity and Adipocyte Clusterin Associates With Cardiometabolic Risk , 2019, Diabetes Care.

[17]  J. Martín-Fernández,et al.  Proteomic Identification of Biomarkers Associated with Eating Control and Bariatric Surgery Outcomes in Patients with Morbid Obesity , 2018, World Journal of Surgery.

[18]  Y. Shim,et al.  Hepatocyte-specific clusterin overexpression attenuates diet-induced nonalcoholic steatohepatitis. , 2018, Biochemical and biophysical research communications.

[19]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[20]  M. Wilson,et al.  Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses , 2016, Cell Death and Disease.

[21]  J. Ordóñez‐Llanos,et al.  Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. , 2015, Atherosclerosis.

[22]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[23]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[24]  Min-Seon Kim,et al.  Plasma Clusterin (ApoJ) Levels Are Associated with Adiposity and Systemic Inflammation , 2014, PloS one.

[25]  Jian-Gao Fan,et al.  Epidemiology of alcoholic and nonalcoholic fatty liver disease in China , 2013, Journal of gastroenterology and hepatology.

[26]  Joo-Yong Lee,et al.  Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway , 2013, Nature Communications.

[27]  In-kyu Lee,et al.  Clusterin decreases hepatic SREBP-1c expression and lipid accumulation. , 2013, Endocrinology.

[28]  G. Tarantino,et al.  Is visceral fat reduction necessary to favour metabolic changes in the liver? , 2012, Journal of gastrointestinal and liver diseases : JGLD.

[29]  P. Dandona,et al.  Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery. , 2012, The Journal of clinical endocrinology and metabolism.

[30]  Takeo Kato,et al.  Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.

[31]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[32]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[33]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[34]  C. Mantzoros,et al.  Circulating ApoJ is closely associated with insulin resistance in human subjects. , 2018, Metabolism: clinical and experimental.

[35]  [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. , 2018, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.